STAT
AUGUST 6, 2024
Roche, the Swiss pharmaceutical giant, earlier this year abruptly cancelled an international clinical trial of a drug being studied to treat children with a rare genetic disorder, citing “trade-offs made … to increase the overall portfolio value.” The news stunned parents of children enrolled in the Phase 2 study, as well as the academic researchers running it.
PharmaVoice
AUGUST 6, 2024
An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
AUGUST 6, 2024
Many chefs describe the television series “The Bear” as an accurate portrayal of the demands of a restaurant kitchen. I believe it can also be seen as a characterization of work in a hospital, in which future physicians are simultaneously gaining remarkable skills and enduring career-altering abuse. For my new book, “Progress Notes,” I spent a couple years observing seven medical students in an experimental curriculum.
Pharma Times
AUGUST 6, 2024
Neurological conditions, including Alzheimer’s disease, are the leading cause of ill health globally
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
AUGUST 6, 2024
Life science venture capital firms are pacing for another record-low year of fundraising, potentially hindering the amount of money that startups can draw from over the next several years. In the first half of the year, the industry’s VC firms have raised just 15 pools of capital from wealthy individuals, sovereign wealth funds, pension funds, or university endowments.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
AUGUST 6, 2024
Retirements from the Food and Drug Administration are hardly shocking, especially in the wake of pandemic burnout. But when longtime medical device director Jeff Shuren announced his departure in July, the device world was stunned. Industry leaders, patient advocates, and FDA colleagues alike had grown accustomed to the ambitious, politically-savvy regulator.
pharmaphorum
AUGUST 6, 2024
Discover how the innovative geko device is driving clinical change in UK stroke care. Learn how this technology is revolutionising the treatment and management of stroke patients.
STAT
AUGUST 6, 2024
Alcohol policy researchers are fuming over a letter sent by members of Congress last month, which criticizes a panel of experts charged with assessing the health risks of drinking alcohol. The letter reflects some of the tensions arising as federal health officials revise dietary guidelines for Americans based on a review of research, including mounting evidence of alcohol-related harms.
BioPharma Dive
AUGUST 6, 2024
The funding from Apple Tree Partners will help the startup advance an antiviral drug pipeline that includes a COVID treatment nearing mid-stage testing.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
AUGUST 6, 2024
The U.S. Congress needs help. It lacks the expertise to do its job in the post-Chevron world. At the end of its most recent term, the Supreme Court cast aside in a 6-3 decision the Chevron deference , which for 40 years required judges to defer to reasonable interpretations by federal agencies of the laws they are charged with administering. To legislate effectively without the Chevron deference, Congress will have to enact laws that leave far less room for interpretation.
BioPharma Dive
AUGUST 6, 2024
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
STAT
AUGUST 6, 2024
Arie Belldegrun has yet another job: He wants to be your lender. On Tuesday, Belledegrun and his team announced they have raised more than $600 million for a new life science credit firm called Symbiotic Capital. Symbiotic said it will provide loans to biotechs, companies manufacturing medical devices and health care tools, sequencing firms, and synthetic biology companies, and more.
pharmaphorum
AUGUST 6, 2024
Discover how Step Pharma is harnessing genetics and developing therapeutics targeting CTPS1 to advance cancer research and enhance clinical success. Learn more about their innovative approach.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
STAT
AUGUST 6, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Jeff Shuren’s FDA legacy: Bringing stability to device regs The news of Jeff Shuren ‘s departure from his long-held role as head of the Food and Drug Administration’s Center for Devices and Radiological Health — which my colleague
BioPharma Dive
AUGUST 6, 2024
Symbiotic Capital, which has $600 million in committed capital, aims to make credit a more accessible tool for life sciences companies.
STAT
AUGUST 6, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. As my editor said, it doesn’t feel like summer given how busy the news cycle has been. It’ll probably be another jittery week for biotech stocks after the big global selloff yesterday and a bunch more earnings coming this week.
PioneerRx
AUGUST 6, 2024
Vacations are coming to an end, the temperature is starting to cool down (depending where you are), and your pharmacy’s workflow might.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
pharmaphorum
AUGUST 6, 2024
There's a new source of funding for life science companies, Symbiotic Capital, which is providing credit as an alternative to other financing routes
Pharmafile
AUGUST 6, 2024
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August 2024 – Pfizer Ltd today announced publication of real-world results from a cohort of the longitudinal, observational Phase 4 THAOS (Transthyretin Amyloidosis Outcomes Survey) study evaluating survival rates among patients with transthyretin cardiac amyloidosis (ATTR-CM) treated […] The post New Real-World Data Published in Journal of Cardia
pharmaphorum
AUGUST 6, 2024
Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.Agenus revealed BMS' decision in a Securities & Exchange Commission (SEC) filing (PDF), saying it was a result of a "broader strategic realignment of their development pipeline which involves other licensed products.
The Pharmacist
AUGUST 6, 2024
Pharmacy bodies have condemned the violence and intimidation taking place as racist riots spread across parts of the UK, while pledging support and solidarity for pharmacy teams. And Community Pharmacy England (CPE) has issued advice for community pharmacies, including if they have to temporarily close if that is advised by police. CPE said that the riots […] The post Pharmacy bodies condemn racial violence as riots spread appeared first on The Pharmacist.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
pharmaphorum
AUGUST 6, 2024
Explore the latest updates and collaborations between the Gates Foundation, UCL, DSRU and more in the May-June 2024 issue of Changing Faces. Learn about their impactful work in government, non-profit, and professional organisation sectors.
Express Pharma
AUGUST 6, 2024
Developing new and innovative drugs has always been a time-consuming and expensive endeavour. On average, it takes 12 to 15 years for a drug to go from molecule to market, with 7 to 10 years dedicated to preclinical research. Unfortunately, only one out of ten drugs that enter clinical trials are approved. Recent research by McKinsey indicates that it costs up to $2.8 billion to develop a new drug.
Pharmaceutical Commerce
AUGUST 6, 2024
ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.
pharmaphorum
AUGUST 6, 2024
Mallinckrodt agrees to sell Therakos to private equity firm CVC $925m, well below the $1.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Express Pharma
AUGUST 6, 2024
Bayer recently announced positive results from the Phase III FINEARTS-HF trial, which showed that the use of Kerendia (finerenone) resulted in a clinically meaningful reduction in the composite endpoint of cardiovascular (CV) death and hospitalisations or urgent clinic visits for heart failure (HF). The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which highlights that Bayer’s Kerendia holds the potential to differentiate
pharmaphorum
AUGUST 6, 2024
Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales but lower profits for the second quarter.Total revenues came in at €11.1 billion ($12.2 billion) in the quarter, ahead of analyst consensus estimates, with pharma leading the charge as it recorded sales up 4.5% to €4.61 billion.
Pharmaceutical Technology
AUGUST 6, 2024
The recent success of diabetes and weight loss medications has spurred more interest in other metabolic disorders.
Expert insights. Personalized for you.
361 
Let's personalize your content